Third Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INC

Explicit Guidance:

• Cash Runway: Current cash, cash equivalents, and marketable securities of $431 million are expected to fund operations into the third quarter of 2028.
• Milestone Payments: An incremental $12 million milestone payment from GSK is expected to be received in Q4 2026 following the selection of a development candidate; additional future payments for three remaining GSK programs are not included in current cash runways.
• R&D Spend Trajectory: R&D expenses are anticipated to increase relative to prior periods to support advancing Phase 2a trials for WVE-007 and progress across the RNA editing pipeline.

Business-Segment Outlook:

• WVE-007 (Obesity):
  • Phase 2a Monotherapy: Enrollment is underway in a global placebo-controlled trial for patients with BMI 35–50 and comorbidities; participants show baseline adiposity levels higher than Phase 1 and aligned with typical Phase 2/3 obesity trials. The study aims to cross the one-year regulatory threshold of >5% weight loss.
  • Phase 2a Combination: Initiated in Q3 2026 evaluating WVE-007 (240mg/400mg) plus trisepatide in patients with BMI 35–50 and Type 2 Diabetes; early 3-month data (body composition) expected later in Q4 2026.
  • Maintenance Trial: On track to initiate a Phase 2 trial in Q4 2026 to evaluate WVE-007 as post-incretin maintenance therapy to prevent weight regain after GLP-1 discontinuation.
  • 600mg Data Release: Data from the Phase 1 single-ascending-dose (SAD) 600mg cohort of the ENLIGHT trial expected in Q4 2026 to further characterize potency, duration, and safety.
• WVE-006 (AATD):
  • Registrational Trial: Planning underway for a single two-year registrational trial aimed at full approval (with a potential one-year interim analysis for accelerated approval). The trial design does not require a separate confirmatory study.
  • Dose Selection: Data from the 600mg monthly dosing cohort of the "Restoration 2" trial expected in Q4 2026 to inform the optimal dose and frequency for the pivotal study.
• WVE-008 (PNPLA3 Liver Disease):
  • Clinical Initiation: On track for a First-in-Human (FIH) study submission (CTA) in 2026 targeting homozygous PNPLA3 I148M liver disease.
• GSK Collaboration:
  • Pipeline Transition: GSK has selected an siRNA candidate to transition to its internal pipeline; GSK has three additional programs advancing toward development candidate status.

Market and Competitive Outlook:

• Obesity Landscape: WVE-007 positions itself as a differentiated alternative to incretins (GLP-1s) by driving fat loss while preserving lean mass (unlike incretins which lose ~40% lean mass) and potentially enabling once or twice-yearly dosing to address chronic therapy burden and weight regain (>70% of patients regain weight after GLP-1 cessation).
• AATD Landscape: Aims to set a new standard of care by addressing both lung and liver manifestations, unlike current IV augmentation which only targets lung (and has no liver impact) and lacks dynamic protein response.
• Competitive Advantage: Proprietary SPINA siRNA design and RNA editing platform provide superior potency and durability compared to industry standards; DNA editing competitors face safety concerns (off-target effects) and payer challenges (one-time high cost).

Macro / Industry Outlook:

• Regulatory Trends: Management observes a shift toward accepting "healthy weight loss" endpoints (body composition via DEXA/MRI over simple scale weight) and expects better harmonization between rare disease hubs (CBER/CDER) and global agencies (FDA/EU).
• Assay Validation: FDA has validated the use of LC-MS assays for WVE-006 to measure M and Z proteins, allowing consistent data tracking throughout development.
• Payer/Market Dynamics: Anticipates payers and providers seeking therapies that mitigate muscle loss and address the economic burden of long-term incretin therapy; sees opportunity for WVE-008 in the 9 million-person US/EU market for PNPLA3 liver disease.

Strategic Initiatives:

• Personnel: Added Monica Vinuk as Chief Business Officer (joined last month) to expand platform licensing, corporate development, and partnership opportunities.
• Platform Expansion: Continuing to push boundaries in hepatic/extrahepatic siRNA, RNA editing, and bifunctional modalities; upcoming Research Day will detail SPINA design and new modalities.
• Partnerships: Actively pursuing partnering discussions for both clinical and preclinical assets (WVE-006, WVE-007, and the platform); GSK collaboration continues to validate the technology with additional candidate selections.

Risks and Headwinds to Outlook:

• Trial Design/Endpoints: Accelerated approval relies on achieving an "MZ-like" phenotype in biomarkers; full approval requires a two-year follow-up within a single trial, contingent on interim analysis success.
• Dosing/Frequency: Optimal dosing interval (e.g., monthly vs. bi-weekly vs. annual) for WVE-006 and WVE-007 is not yet finalized and depends on Q4 600mg data modeling.
• Enrollment/Competition: AATD enrollment relies on leveraging patient registries; obesity trials must differentiate against high-volume incretin therapies regarding market adoption and perceived efficacy in higher BMI populations.
• Safety: Potential risks associated with siRNA/silencing approaches (though WAVE views RNA editing as safer than DNA editing) and tolerability issues for combination therapies with incretins.

Management Tone on the Future:

• Confidence: Highly confident in the ability to meet the >5% weight loss regulatory threshold for WVE-007 given higher baseline adiposity in the Phase 2a cohort.
• Efficiency: Strong emphasis on capital efficiency, citing the "single-trial" design for WVE-006 as a faster, more efficient path to market compared to competitors requiring confirmatory trials.
• Innovation: Optimistic that the "healthy weight loss" paradigm (fat loss + muscle preservation) will shift the regulatory and commercial narrative beyond simple pounds lost.
• Progress: Describes the quarter as a period of "strong execution" with significant advancement across all major programs (WVE-007, WVE-006, WVE-008).

Miscellaneous:

• Timeline Specifics:
  • Q4 2026: 600mg WVE-007 SAD data, WVE-006 600mg monthly data, initiation of WVE-007 Maintenance trial, GSK $12M milestone payment.
  • 2026: CTA submission for WVE-008.
  • Next Year (Post-Q4 2026): First patient enrollment in WVE-006 registrational trial (timing dependent on dose locking).
• Upcoming Events: Annual Research Day next week (featuring Dr. Arun Sanyal on PNPLA3); Obesity Week for WVE-007 presentations.